News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 13, 2021Announced positive data from its Phase Ib SPARK study evaluating CM-101 in NAFLD patients
-
Apr 26, 2021The study aims to further validate the anti-fibrotic and anti-inflammatory activity of CM-101 while providing safety and PK data to support development of the subcutaneous formulation
-
Mar 16, 2021Shares of Chemomab Therapeutics to commence trading on the Nasdaq Capital Market on March 17, 2021 under the new ticker symbol "CMMB"
-
Mar 15, 2021Anchiano shareholders approve all resolutions at shareholder meeting
-
Feb 2, 2021- CM-101 is a first in class CCL24 blocking antibody, that showed a positive safety and tolerability profile in phase I studies and first line evidence of anti-fibrotic activity in a phase Ib study in NAFLD patients
-
Jan 5, 2021- CM-101, a first in class CCL24 blocking antibody, showed excellent safety and tolerability using both IV and SC administration
-
Dec 15, 2020Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need